State Street
CNTB

State Street’s Connect Biopharma Holdings CNTB Stock Holding History

State Street’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,527
Closed -$420K – 4801
2021
Q3 		$420K Buy
+17,527
New +$397K ﹤0.01% 4047

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

State Street's CNTB Position: Q4 2021 in Review

State Street sold out of Connect Biopharma Holdings (CNTB) in Q4 2021, closing a stake of 17,527 shares — an estimated $420K sold.

State Street first reported a position in CNTB in Q3 2021 and held it in 1 quarter. The position peaked at $420K in Q3 2021. 29 funds tracked by Wall St. Rank hold CNTB as of Q4 2021.

  • State Street reported no remaining Connect Biopharma Holdings position as of Q4 2021 after selling out during the quarter.
  • State Street sold 17,527 Connect Biopharma Holdings shares in Q4 2021, an estimated $420K.
  • State Street first reported a position in Connect Biopharma Holdings in Q3 2021 and held it in 1 quarter.
  • State Street's Connect Biopharma Holdings position peaked at $420K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q4 2021.

Based on State Street's 13F filing for Q4 2021, filed 14 Feb 2022.